Our latest focus is trying to bring data to bear on common questions we get asked by clients. Last month the topic was: how well does my device need to perform to get premarket clearance from FDA?

Across contemporary cardiovascular clinical trials, the estimates of expected event rates and effect sizes that investigators use to calculate sample sizes—and funding requirements—often come in ...

DURHAM, N.C., Micell Technologies, Inc. today announced that it has completed its review of the scheduled four-month follow-up on the first 10 patients from the DESSOLVE I first-in-human trial of the ...

NEW HAVEN, Conn., July 13, 2020 (GLOBE NEWSWIRE) -- Trevi Therapeutics, Inc. (Nasdaq: TRVI), a clinical-stage biopharmaceutical company focused on the development and commercialization of Haduvio ...

The trial has reached 75% of the targeted enrollment, and topline results continue to be expected in the first half of 2025 NEW HAVEN, Conn., Dec. 12, 2024 /PRNewswire/ -- Trevi Therapeutics, Inc.

Independent Data Monitoring Statistician reaffirmed current sample size to remain at N=160 The trial has reached 75% of the targeted enrollment, and topline results continue to be expected in the ...